Teva Pharmaceutical Industries (TEVA) Expected to Announce Quarterly Earnings on Wednesday

Teva Pharmaceutical Industries (NYSE:TEVA) is anticipated to release its Q1 2025 earnings data before the market opens on Wednesday, May 7th. Analysts expect Teva Pharmaceutical Industries to post earnings of $0.47 per share and revenue of $3.99 billion for the quarter.

Teva Pharmaceutical Industries Trading Up 1.3 %

Teva Pharmaceutical Industries stock opened at $16.40 on Tuesday. Teva Pharmaceutical Industries has a one year low of $12.47 and a one year high of $22.80. The business’s fifty day moving average is $15.10 and its 200 day moving average is $17.48. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The stock has a market capitalization of $18.59 billion, a PE ratio of -11.31, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62.

Wall Street Analyst Weigh In

Several analysts recently issued reports on TEVA shares. UBS Group cut their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Piper Sandler lifted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Wednesday, April 23rd. Bank of America cut their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Finally, Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research note on Monday, April 28th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.